dorzolamide and Chagas-Disease

dorzolamide has been researched along with Chagas-Disease* in 1 studies

Other Studies

1 other study(ies) available for dorzolamide and Chagas-Disease

ArticleYear
Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
    Journal of medicinal chemistry, 2013, Feb-28, Volume: 56, Issue:4

    An α-carbonic anhydrase (CA, EC 4.2.1.1) has been identified, cloned, and characterized from the unicellular protozoan Trypanosoma cruzi, the causative agent of Chagas disease. The enzyme (TcCA) has a very high catalytic activity for the CO2 hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle. A large number of aromatic/heterocyclic sulfonamides and some 5-mercapto-1,3,4-thiadiazoles were investigated as TcCA inhibitors. The aromatic sulfonamides were weak inhibitors (K(I) values of 192 nM to 84 μM), whereas some heterocyclic compounds inhibited the enzyme with K(I) values in the range 61.6-93.6 nM. The thiols were the most potent in vitro inhibitors (K(I) values of 21.1-79.0 nM), and some of them also inhibited the epimastigotes growth of two T. cruzi strains in vivo.

    Topics: Amino Acid Sequence; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Chagas Disease; Cloning, Molecular; Humans; Molecular Sequence Data; Phylogeny; Protozoan Proteins; Structure-Activity Relationship; Sulfhydryl Compounds; Sulfonamides; Thiadiazoles; Trypanocidal Agents; Trypanosoma cruzi

2013